Opinion|Videos|October 6, 2026
Building an Interventional TRD Practice: From Setup to the Patient Experience
Author(s)Ben Yudkoff, MD, Gene Dolgin
Led by the moderator, the panelists discuss the legal, insurance credentialing, DEA licensure, REMS certification, and medication-acquisition steps behind opening a ketamine and esketamine practice, followed by staffing, systems, and outreach.
Advertisement
Episodes in this series
In ‘Building an Interventional TRD Practice: From Setup to the Patient Experience,’ our panel delves into the following critical questions:
What does standing up an interventional practice for treatment-resistant depression actually involve?
What does esketamine treatment for treatment-resistant depression require of patients in time, travel, and monitoring, and how does that shape access?
Led by the moderator, the panelists discuss the legal, insurance credentialing, DEA licensure, REMS certification, and medication-acquisition steps behind opening a ketamine and esketamine practice, followed by staffing, systems, and outreach. They also describe how the 2-hour on-site observation window and the need for a ride home shape access, and how Lumin Health designs each patient’s experience from arrival to departure.
Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.
Our next episode, ‘Advice for Clinicians Considering an Interventional TRD Practice,’ further explores treatment-resistant depression, highlighting what clinicians should weigh before opening a practice and what makes the work worthwhile.
Advertisement
Related to this article
A remitted patient with ARFID faces panic after a crash, showing why recovery includes somatic fear, not just eating behavior.
Lisa Harding, MD, urges psychiatrists to gather histories, deprescribe safely, and send focused sleep referrals now that orexin agonists have arrived for narcolepsy.
Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Explore PTSD prevalence, comorbidities, and first-line care as we invite clinicians to share cases and research.
Veterans younger than 30 starting antidepressants, and anyone coprescribed opioids and benzodiazepines, will need to sign consent forms starting in 2027.
How genes and early stress interact to shape antisocial behavior, from dopamine and serotonin pathways to MAOA and oxytocin findings.
Policy shifts have opened the door to telehealth buprenorphine for pregnant and postpartum women with OUD, but research, guidelines, and state policy lag behind.
Advertisement
Advertisement